RESUMEN
The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab, and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
Asunto(s)
Anticuerpos Monoclonales/química , Inmunoterapia/métodos , Linfoma de Células B/terapia , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20/química , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ensayos Clínicos como Asunto , Epítopos/química , Humanos , Oncología Médica/métodos , Rituximab , Resultado del TratamientoRESUMEN
The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Linfoma de Células B/tratamiento farmacológico , Alemtuzumab , Anticuerpos Monoclonales Humanizados , Anticuerpos Monoclonales de Origen Murino , Anticuerpos Antineoplásicos/uso terapéutico , Ensayos Clínicos como Asunto , Humanos , RituximabRESUMEN
INTRODUCTION: Anorectal cancers are highly curable malignancies. Combined modality treatment with chemotherapy and radiation has dramatically improved both disease-free and overall survival. Little is known about symptomatic complications of treatment. METHODS: Case report based on chart review. RESULTS: Two patients presented with painful anal lesions that were diagnosed as squamous cell carcinoma of the anus. Despite successful treatment with chemotherapy and radiation, their pain syndromes worsened after treatment with development of a lumbosacral plexopathy that required regular followup, imaging, and pain medications. CONCLUSION: Pain syndromes may worsen after successful treatment given with curative intent, and may be a form of treatment toxicity. IMPLICATIONS FOR CANCER SURVIVORS: Treatment related lumbosacral plexopathy may be an unrecognized consequence of the successful treatment of anal carcinoma. These symptoms can be controlled with analgesics.